NCT06248242 (TASPE) is a Phase 4 clinical trial of Edaravone dexborneol in Acute Ischemic Stroke, sponsored by The Second Hospital of Hebei Medical University.

Who is sponsoring NCT06248242?

NCT06248242 is sponsored by The Second Hospital of Hebei Medical University.

What drugs are being tested in NCT06248242?

Interventions in NCT06248242: Edaravone dexborneol.

What condition does NCT06248242 study?

NCT06248242 studies Acute Ischemic Stroke.

Is NCT06248242 still recruiting?

NCT06248242 is currently status unknown. Last updated 8 February 2024.

Last reviewed 2024-02-08 · How we verify

NCT06248242: TASPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol

Status unknown Phase 4 Last updated 8 February 2024

What this trial tests

Phase 4 trial testing Edaravone dexborneol in Acute Ischemic Stroke in 400 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	The Second Hospital of Hebei Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	400
Start date	1 June 2021
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	1 location across China

Drugs / interventions tested

Edaravone dexborneol — full drug profile →

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →

Sponsor

The Second Hospital of Hebei Medical University

Who can join

Adults 18 to 80, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, a multicenter, randomized, controlled, prospective cohort study was conducted to observe the effect of Edaravone Dexborneol on the incidence and outcome of bleeding transformation after thrombolysis in acute ischemic stroke. To explore the methods to reduce the dilemma of bleeding transformation after thrombolysis, and to dynamically detect the changes of the main links causing bleeding transformation such as blood-brain barrier damage, local immune response activation and so on. To explore the mechanism of Edaravone Dexborneol in reducing bleeding transformation. It is proved that Edaravone Dexborneol combined with thrombolytic therapy can reduce the risk of bleeding and transformation after thrombolysis and improve the safety of thrombolysis. Secondly, it can improve the early recanalization rate of ischemic stroke patients after thrombolytic therapy, and effectively protect the integrity of the blood-brain barrier.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Neuroinflammation and acute ischemic stroke: impact on translational research and clinical care.
Levinson S, Pulli B, Heit JJ. · · 2025 · cited 7× · PMID 40356948 · DOI 10.3389/fsurg.2025.1501359
Targeting Neutrophil Extracellular Traps: A New Strategy for the Treatment of Acute Ischemic Stroke Based on Thrombolysis Resistance.
Huang G, Wu H, Lin B, Deng D, et al · · 2026 · cited 3× · PMID 40461018 · DOI 10.1055/a-2609-3457

Verify or expand the search:

Other trials of Edaravone dexborneol

Trials testing the same drug.

NCT06645522 — Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke · Phase 4 · not yet recruiting

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other The Second Hospital of Hebei Medical University trials

Trials by the same sponsor.

NCT07117422 — Venetoclax-Decitabine in Untreated Elderly/Unfit AML · NA · recruiting
NCT04524741 — Use of Intracardiac Echocardiography or Left Atrial Appendage Radiography to Guide Implantation of a Left Atrial Appenda · NA · unknown
NCT04524780 — Use of Intracardiac Echocardiography or Left Atrial Appendage Radiography to Guide Implantation of a Left Atrial Appenda · NA · unknown
NCT05930262 — Acupuncture Therapy Combined With Breathing Training for Patients With Stroke Complicated · NA · completed
NCT04247659 — Study on the Relationship Between Asymmetric Vascular Sign of Cortex and Prognosis in Massive Cerebral Infarction · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06248242 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Hebei Medical University
Last refreshed: 8 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06248242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing